135 related articles for article (PubMed ID: 16334907)
1. The natural history of a novel, systemic, disseminated model of syngeneic mouse B-cell lymphoma.
Passineau MJ; Siegal GP; Everts M; Pereboev A; Jhala D; Wang M; Zhu ZB; Park SK; Curiel DT; Nelson GM
Leuk Lymphoma; 2005 Nov; 46(11):1627-1638. PubMed ID: 16334907
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of intracerebral lymphoma growth delineated in a syngeneic mouse model of central nervous system lymphoma.
Montesinos-Rongen M; Sánchez-Ruiz M; Brunn A; Hong K; Bens S; Perales SR; Cigudosa JC; Siebert R; Deckert M
J Neuropathol Exp Neurol; 2013 Apr; 72(4):325-36. PubMed ID: 23481709
[TBL] [Abstract][Full Text] [Related]
3. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody.
Tutt AL; O'Brien L; Hussain A; Crowther GR; French RR; Glennie MJ
J Immunol; 2002 Mar; 168(6):2720-8. PubMed ID: 11884438
[TBL] [Abstract][Full Text] [Related]
4. In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy.
Schliemann C; Roesli C; Kamada H; Borgia B; Fugmann T; Klapper W; Neri D
Blood; 2010 Jan; 115(3):736-44. PubMed ID: 19903902
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-12-induced cytotoxicity against syngeneic B cell lymphomas of SJL/J mice.
Wajchman J; Simmons WJ; Klein A; Koneru M; Ponzio NM
Leuk Res; 2002 Jun; 26(6):577-90. PubMed ID: 12007506
[TBL] [Abstract][Full Text] [Related]
6. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
[TBL] [Abstract][Full Text] [Related]
7. Diffuse large B-cell lymphoma arising from a multicentric mixed variant of Castleman's disease.
Venizelos I; Tamiolakis D; Simopoulos C; Nikolaidou S; Barbagadaki S; Lambropoulou M; Alexiadis G; Boglou P; Papadopoulos N
Indian J Cancer; 2004; 41(3):135-7. PubMed ID: 15472414
[TBL] [Abstract][Full Text] [Related]
8. A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma.
Amini RM; Berglund M; Rosenquist R; Von Heideman A; Lagercrantz S; Thunberg U; Bergh J; Sundström C; Glimelius B; Enblad G
Leuk Lymphoma; 2002 Nov; 43(11):2179-89. PubMed ID: 12533045
[TBL] [Abstract][Full Text] [Related]
9. Non-Hodgkin's B-cell lymphoma of a lumbar nerve root: a rare cause of lumbar radiculopathy.
Tsai MC
J Clin Neurosci; 2013 Jul; 20(7):1029-31. PubMed ID: 23587602
[TBL] [Abstract][Full Text] [Related]
10. A simple, clinically relevant therapeutic vaccine shows long-term protection in an aggressive, delayed-treatment B lymphoma model.
Pradhan P; Leleux J; Liu J; Roy K
JCI Insight; 2017 Nov; 2(22):. PubMed ID: 29202455
[TBL] [Abstract][Full Text] [Related]
11. Effect of shRNA targeting mouse CD99L2 gene in a murine B cell lymphoma in vitro and in vivo.
Liu F; Zhang G; Liu F; Zhou X; Chen X; Han X; Wu Z; Zhao T
Oncol Rep; 2013 Apr; 29(4):1405-14. PubMed ID: 23338758
[TBL] [Abstract][Full Text] [Related]
12. Non-invasive bioluminescence imaging to monitor the immunological control of a plasmablastic lymphoma-like B cell neoplasia after hematopoietic cell transplantation.
Chopra M; Kraus S; Schwinn S; Ritz M; Mattenheimer K; Mottok A; Rosenwald A; Einsele H; Beilhack A
PLoS One; 2013; 8(12):e81320. PubMed ID: 24349055
[TBL] [Abstract][Full Text] [Related]
13. Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.
Kubuschok B; Trepel M
Expert Opin Drug Discov; 2017 Jul; 12(7):733-745. PubMed ID: 28494631
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus-induced human B-cell lymphoma arising in HuPBL-SCID chimeric mice: characterization and the role of CD40 stimulation in their treatment and prevention.
Funakoshi S; Beckwith M; Fanslow W; Longo DL; Murphy WJ
Pathobiology; 1995; 63(3):133-42. PubMed ID: 8821629
[TBL] [Abstract][Full Text] [Related]
15. U-2940, a human B-cell line derived from a diffuse large cell lymphoma sequential to Hodgkin lymphoma.
Sambade C; Berglund M; Lagercrantz S; Sällström J; Reis RM; Enblad G; Glimelius B; Sundström C
Int J Cancer; 2006 Feb; 118(3):555-63. PubMed ID: 16106419
[TBL] [Abstract][Full Text] [Related]
16. Primary cardiac plasmablastic (diffuse large B-cell) lymphoma mimicking left ventricular aneurysm with mural thrombus.
Miller DV; Mookadam F; Mookadam M; Edwards WD; Macon WR
Cardiovasc Pathol; 2007; 16(2):111-4. PubMed ID: 17317545
[TBL] [Abstract][Full Text] [Related]
17. Intravascular B-cell lymphoma following nodal diffuse large B-cell lymphoma.
Katz DA; Miller IJ; Gregory SA
Clin Adv Hematol Oncol; 2010 Sep; 8(9):637-41. PubMed ID: 21157413
[No Abstract] [Full Text] [Related]
18. Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma.
Agrelo R; Setien F; Espada J; Artiga MJ; Rodriguez M; Pérez-Rosado A; Sanchez-Aguilera A; Fraga MF; Piris MA; Esteller M
J Clin Oncol; 2005 Jun; 23(17):3940-7. PubMed ID: 15867203
[TBL] [Abstract][Full Text] [Related]
19. Treatment of the patient with diffuse large B-cell lymphoma with medical co-morbidities: newer therapies needed.
Fayad L; Hagemeister F
Leuk Lymphoma; 2007 Apr; 48(4):657-8. PubMed ID: 17454622
[No Abstract] [Full Text] [Related]
20. Enhancement of antigen-presenting ability of B lymphoma cells by immunostimulatory CpG-oligonucleotides and anti-CD40 antibody.
Chen W; Yu Y; Shao C; Zhang M; Wang W; Zhang L; Cao X
Immunol Lett; 2001 May; 77(1):17-23. PubMed ID: 11348665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
